• Je něco špatně v tomto záznamu ?

The optimal number of induction chemotherapy cycles in clinically lymph node-positive bladder cancer

M. von Deimling, LS. Mertens, M. Furrer, R. Li, GAH. Tendijck, J. Taylor, F. Crocetto, M. Maas, A. Mari, R. Pichler, M. Moschini, KH. Tully, D. D'Andrea, E. Laukhtina, F. Del Giudice, G. Marcq, M. Velev, A. Gallioli, S. Albisinni, K. Mori, A....

. 2024 ; 134 (1) : 119-127. [pub] 20240312

Jazyk angličtina Země Anglie, Velká Británie

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc24013410

OBJECTIVE: To investigate the optimal number of induction chemotherapy cycles needed to achieve a pathological response in patients with clinically lymph node-positive (cN+) bladder cancer (BCa) who received three or four cycles of induction chemotherapy followed by consolidative radical cystectomy (RC) with pelvic lymph node dissection. PATIENTS AND METHODS: We included 388 patients who received three or four cycles of cisplatin/gemcitabine or (dose-dense) methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC), followed by consolidative RC for cTanyN1-3M0 BCa. We compared pathological complete (pCR = ypT0N0) and objective response (pOR = yp ≤T1N0) between treatment groups. Predictors of pCR and/or pOR were assessed using uni- and multivariable logistic regression analysis. The secondary endpoints were overall (OS) and cancer-specific survival (CSS). We evaluated the association between the number of induction chemotherapy cycles administered and survival outcomes on multivariable Cox regression. RESULTS: Overall, 101 and 287 patients received three or four cycles of induction chemotherapy, respectively. Of these, 72 (19%) and 128 (33%) achieved pCR and pOR response, respectively. The pCR (20%, 18%) and pOR (40%, 31%) rates did not differ significantly between patients receiving three or four cycles (P > 0.05). The number of cycles was not associated with pCR or pOR on multivariable logistic regression analyses. The 2-year OS estimates were 63% (95% confidence interval [CI] 0.53-0.74) and 63% (95% CI 0.58-0.7) for patients receiving three or four cycles, respectively. Receiving three vs four cycles was not associated with OS and CSS on uni- or multivariable Cox regression analyses. CONCLUSION: Pathological response and survival outcomes did not differ between administering three or four induction chemotherapy cycles in patients with cN+ BCa. A fewer cycles (minimum three) may be oncologically sufficient in patients with cN+ BCa, while decreasing the wait for definitive local therapy in those patients who end up without a response to chemotherapy. This warrants further validation.

CNRS Inserm CHU Lille Institut Pasteur de Lille UMR9020 U1277 CANTHER Cancer Heterogeneity Plasticity and Resistance to Therapies University of Lille Lille France

Department of Cancer Medicine Gustave Roussy Université Paris Saclay Villejuif France

Department of Genitourinary Oncology H Lee Moffitt Cancer Center and Research Institute Tampa FL USA

Department of Maternal Infant and Urologic Sciences Policlinico Umberto 1 Hospital Sapienza University of Rome Rome Italy

Department of Neurosciences Reproductive Sciences and Odontostomatology University of Naples Federico 2 Naples Italy

Department of Urologic Sciences University of British Columbia Vancouver BC Canada

Department of Urology 2nd Faculty of Medicine Charles University Prague Czech Republic

Department of Urology and Neurourology Marien Hospital Herne Ruhr University Bochum Herne Germany

Department of Urology CHU Lille Claude Huriez Hospital Lille France

Department of Urology Comprehensive Cancer Center Innsbruck Medical University of Innsbruck Innsbruck Austria

Department of Urology Comprehensive Cancer Center Medical University of Vienna Vienna Austria

Department of Urology Eberhard Karls University Tübingen Tübingen Germany

Department of Urology Fundació Puigvert Autonomous University of Barcelona Barcelona Spain

Department of Urology Marienkrankenhaus Hamburg Germany

Department of Urology Mayo Clinic Rochester MN USA

Department of Urology Solothurner Spitäler AG Kantonsspital Olten and Bürgerspital Solothurn Switzerland

Department of Urology The Jikei University School of Medicine Tokyo Japan

Department of Urology The Netherlands Cancer Institute Amsterdam The Netherlands

Department of Urology University Hospital of Bern University of Bern Bern Switzerland

Department of Urology University Medical Center Hamburg Eppendorf Hamburg Germany

Department of Urology University of Texas Southwestern Dallas TX USA

Department of Urology Urological Research Institute Vita Salute San Raffaele Milan Italy

Department of Urology Urosud La Croix Du Sud Hospital Quint Fonsegrives France

Department of Urology Weill Cornell Medical College New York NY USA

Hourani Center for Applied Scientific Research Al Ahliyya Amman University Amman Jordan

Karl Landsteiner Institute of Urology and Andrology Vienna Austria

Service d'Urologie Hôpital Erasme Université Libre de Bruxelles Bruxelles Belgium

Unit of Oncologic Minimally Invasive Urology and Andrology Department of Experimental and Clinical Medicine Careggi Hospital University of Florence Florence Italy

Urology Unit Department of Surgical Sciences Tor Vergata University Hospital University of Rome Tor Vergata Rome Italy

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc24013410
003      
CZ-PrNML
005      
20240905134037.0
007      
ta
008      
240725s2024 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1111/bju.16319 $2 doi
035    __
$a (PubMed)38470089
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a von Deimling, Markus $u Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria $u Department of Urology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany $1 https://orcid.org/0000000299543413
245    14
$a The optimal number of induction chemotherapy cycles in clinically lymph node-positive bladder cancer / $c M. von Deimling, LS. Mertens, M. Furrer, R. Li, GAH. Tendijck, J. Taylor, F. Crocetto, M. Maas, A. Mari, R. Pichler, M. Moschini, KH. Tully, D. D'Andrea, E. Laukhtina, F. Del Giudice, G. Marcq, M. Velev, A. Gallioli, S. Albisinni, K. Mori, A. Khanna, M. Rink, M. Fisch, A. Minervini, PC. Black, Y. Lotan, PE. Spiess, B. Kiss, SF. Shariat, B. Pradere, CLIPOLY Study Group Collaborators
520    9_
$a OBJECTIVE: To investigate the optimal number of induction chemotherapy cycles needed to achieve a pathological response in patients with clinically lymph node-positive (cN+) bladder cancer (BCa) who received three or four cycles of induction chemotherapy followed by consolidative radical cystectomy (RC) with pelvic lymph node dissection. PATIENTS AND METHODS: We included 388 patients who received three or four cycles of cisplatin/gemcitabine or (dose-dense) methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC), followed by consolidative RC for cTanyN1-3M0 BCa. We compared pathological complete (pCR = ypT0N0) and objective response (pOR = yp ≤T1N0) between treatment groups. Predictors of pCR and/or pOR were assessed using uni- and multivariable logistic regression analysis. The secondary endpoints were overall (OS) and cancer-specific survival (CSS). We evaluated the association between the number of induction chemotherapy cycles administered and survival outcomes on multivariable Cox regression. RESULTS: Overall, 101 and 287 patients received three or four cycles of induction chemotherapy, respectively. Of these, 72 (19%) and 128 (33%) achieved pCR and pOR response, respectively. The pCR (20%, 18%) and pOR (40%, 31%) rates did not differ significantly between patients receiving three or four cycles (P > 0.05). The number of cycles was not associated with pCR or pOR on multivariable logistic regression analyses. The 2-year OS estimates were 63% (95% confidence interval [CI] 0.53-0.74) and 63% (95% CI 0.58-0.7) for patients receiving three or four cycles, respectively. Receiving three vs four cycles was not associated with OS and CSS on uni- or multivariable Cox regression analyses. CONCLUSION: Pathological response and survival outcomes did not differ between administering three or four induction chemotherapy cycles in patients with cN+ BCa. A fewer cycles (minimum three) may be oncologically sufficient in patients with cN+ BCa, while decreasing the wait for definitive local therapy in those patients who end up without a response to chemotherapy. This warrants further validation.
650    _2
$a lidé $7 D006801
650    12
$a nádory močového měchýře $x farmakoterapie $x patologie $x mortalita $7 D001749
650    _2
$a mužské pohlaví $7 D008297
650    12
$a indukční chemoterapie $7 D060828
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé středního věku $7 D008875
650    _2
$a senioři $7 D000368
650    12
$a protokoly antitumorózní kombinované chemoterapie $x terapeutické užití $7 D000971
650    12
$a cystektomie $x metody $7 D015653
650    12
$a lymfatické metastázy $7 D008207
650    _2
$a retrospektivní studie $7 D012189
650    _2
$a výsledek terapie $7 D016896
650    _2
$a gemcitabin $7 D000093542
650    _2
$a cisplatina $x aplikace a dávkování $7 D002945
650    _2
$a lymfadenektomie $7 D008197
650    _2
$a methotrexát $x aplikace a dávkování $7 D008727
650    _2
$a lymfatické uzliny $x patologie $7 D008198
650    _2
$a deoxycytidin $x analogy a deriváty $x aplikace a dávkování $7 D003841
655    _2
$a časopisecké články $7 D016428
700    1_
$a Mertens, Laura S $u Department of Urology, The Netherlands Cancer Institute, Amsterdam, The Netherlands $1 https://orcid.org/0000000333176427
700    1_
$a Furrer, Marc $u Department of Urology, University Hospital of Bern, University of Bern, Bern, Switzerland $u Department of Urology, Solothurner Spitäler AG, Kantonsspital Olten and Bürgerspital Solothurn, Switzerland $1 https://orcid.org/0000000188476799
700    1_
$a Li, Roger $u Department of Genitourinary Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA $1 https://orcid.org/0000000312747200
700    1_
$a Tendijck, Guus A H $u Department of Urology, The Netherlands Cancer Institute, Amsterdam, The Netherlands
700    1_
$a Taylor, Jacob $u Department of Urology, University of Texas Southwestern, Dallas, TX, USA
700    1_
$a Crocetto, Felice $u Department of Neurosciences, Reproductive Sciences and Odontostomatology, University of Naples "Federico II", Naples, Italy
700    1_
$a Maas, Moritz $u Department of Urology, Eberhard Karls University Tübingen, Tübingen, Germany $u Department of Urologic Sciences, University of British Columbia, Vancouver, BC, Canada
700    1_
$a Mari, Andrea $u Unit of Oncologic Minimally-Invasive Urology and Andrology, Department of Experimental and Clinical Medicine, Careggi Hospital, University of Florence, Florence, Italy $1 https://orcid.org/0000000190705706
700    1_
$a Pichler, Renate $u Department of Urology, Comprehensive Cancer Center Innsbruck, Medical University of Innsbruck, Innsbruck, Austria $1 https://orcid.org/0000000152869048
700    1_
$a Moschini, Marco $u Department of Urology, Urological Research Institute, Vita-Salute San Raffaele, Milan, Italy $1 https://orcid.org/0000000230842458
700    1_
$a Tully, Karl H $u Department of Urology and Neurourology, Marien Hospital Herne, Ruhr-University Bochum, Herne, Germany $1 https://orcid.org/0000000294990169
700    1_
$a D'Andrea, David $u Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria $1 https://orcid.org/0000000316251077
700    1_
$a Laukhtina, Ekaterina $u Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria $1 https://orcid.org/0000000289530272
700    1_
$a Del Giudice, Francesco $u Department of Maternal Infant and Urologic Sciences, Policlinico Umberto I Hospital, "Sapienza" University of Rome, Rome, Italy $1 https://orcid.org/0000000338655988
700    1_
$a Marcq, Gautier $u Department of Urology, CHU Lille, Claude Huriez Hospital, Lille, France $u CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, UMR9020-U1277 - CANTHER - Cancer Heterogeneity Plasticity and Resistance to Therapies, University of Lille, Lille, France
700    1_
$a Velev, Maud $u Department of Cancer Medicine, Gustave Roussy, Université Paris-Saclay, Villejuif, France
700    1_
$a Gallioli, Andrea $u Department of Urology, Fundació Puigvert, Autonomous University of Barcelona, Barcelona, Spain $1 https://orcid.org/0000000233165691
700    1_
$a Albisinni, Simone $u Urology Unit, Department of Surgical Sciences, Tor Vergata University Hospital, University of Rome Tor Vergata, Rome, Italy $u Service d'Urologie, Hôpital Erasme, Université Libre de Bruxelles, Bruxelles, Belgium $1 https://orcid.org/0000000155293064
700    1_
$a Mori, Keiichiro $u Department of Urology, The Jikei University School of Medicine, Tokyo, Japan $1 https://orcid.org/0000000261476569
700    1_
$a Khanna, Abhinav $u Department of Urology, Mayo Clinic, Rochester, MN, USA
700    1_
$a Rink, Michael $u Department of Urology, Marienkrankenhaus, Hamburg, Germany
700    1_
$a Fisch, Margit $u Department of Urology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
700    1_
$a Minervini, Andrea $u Unit of Oncologic Minimally-Invasive Urology and Andrology, Department of Experimental and Clinical Medicine, Careggi Hospital, University of Florence, Florence, Italy
700    1_
$a Black, Peter C $u Department of Urologic Sciences, University of British Columbia, Vancouver, BC, Canada
700    1_
$a Lotan, Yair $u Department of Urology, University of Texas Southwestern, Dallas, TX, USA $1 https://orcid.org/0000000156922723
700    1_
$a Spiess, Philippe E $u Department of Genitourinary Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA
700    1_
$a Kiss, Bernhard $u Department of Urology, University Hospital of Bern, University of Bern, Bern, Switzerland $1 https://orcid.org/000000024691556X
700    1_
$a Shariat, Shahrokh F $u Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria $u Karl Landsteiner Institute of Urology and Andrology, Vienna, Austria $u Department of Urology, University of Texas Southwestern, Dallas, TX, USA $u Department of Urology, Weill Cornell Medical College, New York, NY, USA $u Hourani Center for Applied Scientific Research, Al-Ahliyya Amman University, Amman, Jordan $u Department of Urology, Second Faculty of Medicine, Charles University, Prague, Czech Republic
700    1_
$a Pradere, Benjamin $u Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria $u Department of Urology, Urosud, La Croix Du Sud Hospital, Quint-Fonsegrives, France
710    2_
$a CLIPOLY Study Group Collaborators
773    0_
$w MED00011371 $t BJU international $x 1464-410X $g Roč. 134, č. 1 (2024), s. 119-127
856    41
$u https://pubmed.ncbi.nlm.nih.gov/38470089 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20240725 $b ABA008
991    __
$a 20240905134031 $b ABA008
999    __
$a ok $b bmc $g 2143307 $s 1225276
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2024 $b 134 $c 1 $d 119-127 $e 20240312 $i 1464-410X $m BJU international $n BJU Int $x MED00011371
LZP    __
$a Pubmed-20240725

Najít záznam

Citační ukazatele

Možnosti archivace